Navigation Links
Should Cystic Fibrosis Patients Get So Many Antibiotics?
Date:3/26/2012

MONDAY, March 26 (HealthDay News) -- Antibiotics can prolong cystic fibrosis patients' lives, but the drugs also help treatment-resistant bacteria thrive in their lungs, a new, small study suggests.

The findings from the 10-year investigation suggest, but do not prove, that the current standard of aggressive antibiotic treatment for cystic fibrosis patients may not always be the best approach.

It's common to use antibiotics to control infection in cystic fibrosis patients' lungs, but maintaining a more diverse range of bacteria in the lungs may help some patients stay healthy longer, according to study senior author Dr. John LiPuma, a research professor of pediatrics and communicable diseases at the University of Michigan Medical School in Ann Arbor.

"The conventional wisdom has been that as patients with cystic fibrosis age and become sicker, as their lung disease progresses, more and more bacteria move in," he said in a university news release. "But our study -- which was the first to examine the bacterial communities in cystic fibrosis patients' lungs over a long period of time -- indicates that's not what happens."

Aggressive use of antibiotics actually lowers the diversity of lung bacteria, resulting in infections that are increasingly difficult to treat. A more diverse community of lung bacteria may help keep the most dangerous strains in check, the researchers noted.

"What we normally do is essentially carpet bombing with antibiotics," explained LiPuma. "However, what we found is that over time this ultimately helps treatment-resistant bacteria by getting rid of their competition."

He said the findings may be a first step toward developing new treatment methods, such as more focused use of antibiotics or even giving cystic fibrosis patients beneficial bacteria.

The study was published March 26 in the Proceedings of the National Academy of Sciences.

Cystic fibrosis is a chronic disease in which the body produces thick, sticky mucus that clogs the lungs. The accumulation of the mucus leaves people prone to serious, hard-to-treat and recurrent infections. Eventually, the repeated infections destroy the lungs.

In the study, researchers examined the bacteria from six patients collected over eight to nine years. Half of the patients had a relatively stable type of the disease and the others had the more typical, faster-progressing form. The investigators conducted DNA analysis on bacteria in 126 sputum samples.

Over time, the researchers found that bacterial diversity declined, yet the overall level of bacteria remained fairly constant. The study authors explained that this means a small number of organisms multiply to take the place of those that have been killed off by antibiotics.

More information

The U.S. National Heart, Lung, and Blood Institute has more about cystic fibrosis.

-- Robert Preidt

SOURCE: University of Michigan, news release, March 26, 2012


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Girl Softball Players Suffering More Shoulder Injuries
2. Anthem Blue Crosss Announcement That It Will Temporarily Suspend a 39% Health Insurance Rate Increase Should Not Deter Immediate Legislative Action
3. NIH Stem Cell Guidelines Should Be Modified, UCSF Team Reports
4. Rate Regulation for Health Insurance: Obama Administration Should Look to CAs Model Law Which Has Saved Drivers $62 Billion Since 1988
5. Virtually Everyone Should Get a Flu Shot: CDC
6. HIV drug that protects a fetus should be avoided for one year after childbirth, researchers say
7. California Dental Hygienists Say National Children's Dental Health Month Should Be a Yearlong Effort
8. Six "Common Sense" Points Not Included In The Health Care Discussion? Should They Be?
9. Six "Common Sense" Points Not Included In The Health Care Discussion? Should They Be?
10. Young Men and Elderly Women at Biggest Risk for Shoulder Dislocations
11. Shoulder Dislocations a Sports Hazard
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Should Cystic Fibrosis Patients Get So Many Antibiotics? 
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
(Date:6/24/2016)... ... , ... National recruitment firm Slone Partners is pleased to announce ... experience, as Vice President of North American Capital Sales at HTG Molecular . ... sales team in the commercialization of the HTG EdgeSeq system and associated reagents in ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016   Bay Area Lyme Foundation , ... Center for Tick Borne Illness , Harvard Medical ... Hacking Medicine, University of California, Berkeley, and the ... five finalists of Lyme Innovation , the ... 100 scientists, clinicians, researchers, entrepreneurs, and investors from ...
(Date:6/24/2016)... , June 24, 2016  American Respiratory Labs (ARL), a ... now able to perform sophisticated lung assessments in patients, homes, thanks ... Inc. Patients are no longer limited to having ... PRO ® , ARL patients like Jeanne R. of ... the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
Breaking Medicine Technology: